RA
CARM

Royce & Associates’s Carisma Therapeutics CARM Stock Holding History

Royce & Associates’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-132
Closed -$5K – 1180
2018
Q2 		$5K Sell
132
-12
-8% -$529 ﹤0.01% 1212
2018
Q1 		$3K Buy
+144
New +$2.76K ﹤0.01% 1249
2015
Q2 		– Sell
-19,430
Closed -$3.47M – 1217
2015
Q1 		$3.47M Buy
+19,430
New +$4.25M 0.01% 826

Other funds holding CARM

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Royce & Associates's CARM Position: Q3 2018 in Review

Royce & Associates sold out of Carisma Therapeutics (CARM) in Q3 2018, closing a stake of 132 shares — an estimated $5K sold.

Royce & Associates first reported a position in CARM in Q1 2015 and held it in 3 quarters. The position peaked at $3.47M in Q1 2015. 47 funds tracked by Wall St. Rank hold CARM as of Q3 2018.

  • Royce & Associates reported no remaining Carisma Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Royce & Associates sold 132 Carisma Therapeutics shares in Q3 2018, an estimated $5K.
  • Royce & Associates first reported a position in Carisma Therapeutics in Q1 2015 and held it in 3 quarters.
  • Royce & Associates's Carisma Therapeutics position peaked at $3.47M in Q1 2015.
  • 47 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2018.

Based on Royce & Associates's 13F filing for Q3 2018, filed 13 Nov 2018.